These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

983 related articles for article (PubMed ID: 32199096)

  • 1. Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study.
    He A; Merkel B; Brown JWL; Zhovits Ryerson L; Kister I; Malpas CB; Sharmin S; Horakova D; Kubala Havrdova E; Spelman T; Izquierdo G; Eichau S; Trojano M; Lugaresi A; Hupperts R; Sola P; Ferraro D; Lycke J; Grand'Maison F; Prat A; Girard M; Duquette P; Larochelle C; Svenningsson A; Petersen T; Grammond P; Granella F; Van Pesch V; Bergamaschi R; McGuigan C; Coles A; Hillert J; Piehl F; Butzkueven H; Kalincik T;
    Lancet Neurol; 2020 Apr; 19(4):307-316. PubMed ID: 32199096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disease-modifying therapies in managing disability worsening in paediatric-onset multiple sclerosis: a longitudinal analysis of global and national registries.
    Sharmin S; Roos I; Malpas CB; Iaffaldano P; Simone M; Filippi M; Kubala Havrdova E; Ozakbas S; Brescia Morra V; Alroughani R; Zaffaroni M; Patti F; Eichau S; Salemi G; Di Sapio A; Inglese M; Portaccio E; Trojano M; Amato MP; Kalincik T; ;
    Lancet Child Adolesc Health; 2024 May; 8(5):348-357. PubMed ID: 38547883
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in the Risk of Reaching Multiple Sclerosis Disability Milestones In Recent Decades: A Nationwide Population-Based Cohort Study in Sweden.
    Beiki O; Frumento P; Bottai M; Manouchehrinia A; Hillert J
    JAMA Neurol; 2019 Jun; 76(6):665-671. PubMed ID: 30882868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis.
    Roos I; Hughes S; McDonnell G; Malpas CB; Sharmin S; Boz C; Alroughani R; Ozakbas S; Buzzard K; Skibina O; van der Walt A; Butzkueven H; Lechner-Scott J; Kuhle J; Terzi M; Laureys G; Van Hijfte L; John N; Grammond P; Grand'Maison F; Soysal A; Jensen AV; Rasmussen PV; Svendsen KB; Barzinji I; Nielsen HH; Sejbæk T; Prakash S; Stilund MLM; Weglewski A; Issa NM; Kant M; Sellebjerg F; Gray O; Magyari M; Kalincik T;
    JAMA Neurol; 2023 Aug; 80(8):789-797. PubMed ID: 37307006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long term effect of delayed treatment on disability in patients with paediatric onset multiple sclerosis: A prospective Danish cohort study.
    Kopp TI; Blinkenberg M; Petersen T; Sorensen PS; Magyari M
    Mult Scler Relat Disord; 2020 May; 40():101956. PubMed ID: 32007654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Rituximab Treatment With Disability Progression Among Patients With Secondary Progressive Multiple Sclerosis.
    Naegelin Y; Naegelin P; von Felten S; Lorscheider J; Sonder J; Uitdehaag BMJ; Scotti B; Zecca C; Gobbi C; Kappos L; Derfuss T
    JAMA Neurol; 2019 Mar; 76(3):274-281. PubMed ID: 30615019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
    Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early clinical markers of aggressive multiple sclerosis.
    Malpas CB; Manouchehrinia A; Sharmin S; Roos I; Horakova D; Havrdova EK; Trojano M; Izquierdo G; Eichau S; Bergamaschi R; Sola P; Ferraro D; Lugaresi A; Prat A; Girard M; Duquette P; Grammond P; Grand'Maison F; Ozakbas S; Van Pesch V; Granella F; Hupperts R; Pucci E; Boz C; Sidhom Y; Gouider R; Spitaleri D; Soysal A; Petersen T; Verheul F; Karabudak R; Turkoglu R; Ramo-Tello C; Terzi M; Cristiano E; Slee M; McCombe P; Macdonell R; Fragoso Y; Olascoaga J; Altintas A; Olsson T; Butzkueven H; Hillert J; Kalincik T
    Brain; 2020 May; 143(5):1400-1413. PubMed ID: 32386427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term outcomes in patients presenting with optic neuritis: Analyses of the MSBase registry.
    Kenney R; Liu M; Patil S; Alroughani R; Ampapa R; Bergamaschi R; Boz C; Butzkueven H; Gomez JC; Cartechini E; Madueño SE; Ferraro D; Grand-Maison F; Granella F; Horakova D; Izquierdo Ayuso G; Kalincik T; Lizrova Preiningerova J; Lugaresi A; Onofrj M; Ozakbas S; Patti F; Sola P; Soysal A; Spitaleri DLA; Terzi M; Turkoglu R; van Pesch V; Saidha S; Thorpe LE; Galetta SL; Balcer LJ; Kister I; Spelman T;
    J Neurol Sci; 2021 Nov; 430():118067. PubMed ID: 34537678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Late-onset and young-onset relapsing-remitting multiple sclerosis: evidence from a retrospective long-term follow-up study.
    D'Amico E; Patti F; Zanghì A; Chisari CG; Lo Fermo S; Zappia M
    Eur J Neurol; 2018 Dec; 25(12):1425-1431. PubMed ID: 29956427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of Persistent Disability in Patients With Pediatric-Onset Multiple Sclerosis.
    Baroncini D; Simone M; Iaffaldano P; Brescia Morra V; Lanzillo R; Filippi M; Romeo M; Patti F; Chisari CG; Cocco E; Fenu G; Salemi G; Ragonese P; Inglese M; Cellerino M; Margari L; Comi G; Zaffaroni M; Ghezzi A;
    JAMA Neurol; 2021 Jun; 78(6):726-735. PubMed ID: 33938921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Characteristics and Long-Term Outcomes of Late-Onset Multiple Sclerosis: A Swedish Nationwide Study.
    Mouresan EF; Mentesidou E; Berglund A; McKay KA; Hillert J; Iacobaeus E
    Neurology; 2024 Mar; 102(6):e208051. PubMed ID: 38394472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does initial high efficacy therapy in multiple sclerosis surpass escalation treatment strategy? A comparison of patients with relapsing-remitting multiple sclerosis in the Czech and Swedish national multiple sclerosis registries.
    Hrnciarova T; Drahota J; Spelman T; Hillert J; Lycke J; Kubala Havrdova E; Recmanova E; Adamkova J; Mares J; Libertinova J; Pavelek Z; Hradilek P; Ampapa R; Stetkarova I; Peterka M; Martinkova A; Stourac P; Grunermelova M; Vachova M; Dufek M; Horakova D
    Mult Scler Relat Disord; 2023 Aug; 76():104803. PubMed ID: 37329786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional Disability and Brain MRI Volumetry Results among Multiple Sclerosis Patients during 5-Year Follow-Up.
    Strautmane S; Balodis A; Teivane A; Grabovska D; Naudins E; Urbanovics D; Fisermans E; Mednieks J; Flintere-Flinte A; Priede Z; Millers A; Zolovs M
    Medicina (Kaunas); 2023 Jun; 59(6):. PubMed ID: 37374286
    [No Abstract]   [Full Text] [Related]  

  • 16. Real-world effectiveness of cladribine for Australian patients with multiple sclerosis: An MSBase registry substudy.
    Lizak N; Hodgkinson S; Butler E; Lechner-Scott J; Slee M; McCombe PA; Shaw C; Skibina O; Vucic S; Shuey N; Barnett MH; Parratt J; Butzkueven H; Jack D; Fabris J; Kalincik T
    Mult Scler; 2021 Mar; 27(3):465-474. PubMed ID: 32530363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disability trajectories by progression independent of relapse activity status differ in pediatric, adult and late-onset multiple sclerosis.
    Simone M; Lucisano G; Guerra T; Paolicelli D; Rocca MA; Brescia Morra V; Patti F; Annovazzi P; Gasperini C; De Luca G; Ferraro D; Margari L; Granella F; Pozzilli C; Romano S; Perini P; Bergamaschi R; Coniglio MG; Lus G; Vianello M; Lugaresi A; Portaccio E; Filippi M; Amato MP; Iaffaldano P;
    J Neurol; 2024 Oct; 271(10):6782-6790. PubMed ID: 39179712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early onset multiple sclerosis and the effect of disease onset age on neurological disability in multiple sclerosis.
    Usta NC; Boz C; Terzi M
    Clin Neurol Neurosurg; 2023 Jan; 224():107528. PubMed ID: 36446265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment Escalation vs Immediate Initiation of Highly Effective Treatment for Patients With Relapsing-Remitting Multiple Sclerosis: Data From 2 Different National Strategies.
    Spelman T; Magyari M; Piehl F; Svenningsson A; Rasmussen PV; Kant M; Sellebjerg F; Joensen H; Hillert J; Lycke J
    JAMA Neurol; 2021 Oct; 78(10):1197-1204. PubMed ID: 34398221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glial and neuroaxonal biomarkers in a multiple sclerosis (MS) cohort.
    Kalatha T; Hatzifilippou E; Arnaoutoglou M; Balogiannis S; Koutsouraki E
    Hell J Nucl Med; 2019; 22 Suppl 2():113-121. PubMed ID: 31802051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 50.